Clinical Study | Office of Clinical Research

A Phase 1B/2 Study Of Tergenpumatucel-L (Hyperacute Lung) Immunotherapy In Combination With The Ido Pathway Inhibitor Indoximod And Docetaxel In Pati

Posted Date: May 15, 2019

Investigator: John Morris
Type of Study: Drug

In this clinical study we will look at the safety and anti-tumor effects of the combination of the experimental drugs tergenpumatucel-L immunotherapy and indoximod with the approved drug therapy docetaxel. ?Experimental? means the drug has not been approved by any Authority that regulates new medic

Criteria:

To Be Eligible To Participate, Patients Must Have Been Diagnosed With Cancer Of The Lung.

Keywords:

Cancer, Lung, Nlg-0401, Non Small Cell, Previously Treated

For More Information:

Uc Cancer Center
513-584-7698
kastla@uc.edu

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List